Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718400 | 0.82 | MEN1 (0.51) | MEN1KMT2ALMNASMN1; SMN2HTT | |
| SCHEMBL1548187 | 0.79 | LMNA (0.52) | MEN1KMT2ALMNASMN1; SMN2HTT | |
| SCHEMBL4715003 | 0.77 | GRIN2D (0.48) | MEN1KMT2ALMNASMN1; SMN2HTT | |
| SCHEMBL1548412 | 0.77 | HDAC6 (0.45) | MEN1KMT2ALMNASMN1; SMN2HTT | |
| SCHEMBL1548949 | 0.77 | SPHK2 (0.74) | MEN1KMT2ALMNASMN1; SMN2HTT | |
| SCHEMBL4716332 | 0.77 | MEN1 (0.52) | MEN1KMT2ALMNASMN1; SMN2HTT | |
| SCHEMBL4717867 | 0.75 | OPRM1 (0.47) | MEN1KMT2ALMNASMN1; SMN2HTT | |
| SCHEMBL1548830 | 0.73 | SPHK2 (0.69) | MEN1KMT2ALMNASMN1; SMN2HTT | |
| SCHEMBL4716912 | 0.73 | SPHK2 (0.52) | MEN1KMT2ALMNASMN1; SMN2HTT | |
| SCHEMBL1549039 | 0.72 | LMNA (0.49) | MEN1KMT2ALMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904439-A2 | SPHINGOSINE KINASE INHIBITORS | Apogee Biothechnology Corporation (US) | 2008-04-02 | — | — | EP | claimed |
| WO-2006138660-A2 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2006-12-28 | — | — | WO | claimed |
| EP-3407912-A1 | METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2018-12-05 | — | — | EP | disclosed |
| WO-2017129769-A1 | METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-08-03 | — | — | WO | disclosed |
| EP-1904439-A2 | SPHINGOSINE KINASE INHIBITORS | Apogee Biothechnology Corporation (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006138660-A2 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2006-12-28 | — | — | WO | disclosed |